Candidate drug EDP-305 reduced fibrosis progression and improved non-alcoholic fatty liver disease (NAFLD) and primary biliary cholangitis (PBC) disease settings in several preclinical animal models, says…
NV556 inhibited tumor growth in mice with a liver disease known as non-alcoholic steatohepatitis, or NASH, according to a study by its maker, NeuroVive Pharmaceutical AB.
Cerenis Therapeutics has initiated a Phase 1 clinical trial of CER-209 for the treatment of non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD).
The latest preclinical results of Ocera Therapeutics’ ammonia scavenger OCR-002 showed that it can reduce fibrosis progression in animal models of non-alcoholic fatty liver…
Boston-based Albireo Pharma hosted an April 13 breakfast presentation in New York that featured an overview of the company’s clinical programs as well as a talk by…
Galectin Therapeutics’s lead drug GR-MD-02 may be a promising therapeutic approach to treat fibrosis in fatty liver disease — or non-alcoholic steatohepatitis (NASH) — based on results from…
Bozitinib (CBT-101) suppresses the growth of human liver tumors in a laboratory environment, according to its maker, CBT Pharmaceuticals. The oral therapy works by…
Conatus Pharmaceuticals updated participants at two New York medical conferences this month on  its efforts to develop emricasan, which has been shown to improve manifestations…
A new review suggests that statins — used primarily to manage cholesterol — may be effective in treating liver inflammation and chronic liver disease. Statins are…
Thirteen percent of patients with inflammatory bowel disease (IBD) also had non-alcoholic fatty liver disease (NAFLD), according to a Texas study. The overlap occurred despite…